Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-05-24
2005-05-24
Andres, Janet (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069700
Reexamination Certificate
active
06897294
ABSTRACT:
The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 5008196 (1991-04-01), Connolly et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5185438 (1993-02-01), Lemischka
patent: 5240848 (1993-08-01), Keck et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5844099 (1998-12-01), Stahl et al.
patent: 5861484 (1999-01-01), Kendall et al.
patent: 6472179 (2002-10-01), Stahl et al.
patent: 20040014667 (2004-01-01), Daly et al.
patent: WO 9108298 (1991-06-01), None
patent: WO 9214748 (1992-09-01), None
patent: WO 9217486 (1992-10-01), None
patent: WO 9411499 (1994-05-01), None
patent: WO 9421679 (1994-09-01), None
patent: WO 9521868 (1995-08-01), None
patent: WO 9533050 (1995-12-01), None
patent: WO 9533772 (1995-12-01), None
patent: WO 0075319 (2000-12-01), None
Davis-Smyth et al., 1996,EMBO J.,15:4919-4927 “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade”.
DeVries et al., 1992,Science,225:989-991 “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”.
Ferrara et al., 1989,Biochem. Biophys. Res. Comm.,161:851-858 “Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells”.
Folkman et al., 1989,Nature,339:58-61 “Induction of angiogenesis during the transition from hyperplasia to neoplasia”.
Fuh et al., 1998,J. Biol. Chem.,273:11197-111204 “Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor”.
Holash et al., 2002,Proc. Natl. Acad. Sci. USA,99:11393-11398 “VEGF-Trap: A VEGF blocker with potent antitumor effects”.
Kim et al., 1993,Nature,362:841-844 “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo”.
Lee et al., 1996,Proc. Natl. Acad. Sci. USA,93:1988-1992 “Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4”.
Leung et al., 1989,Science,246:1306 “Vascular endothelial growth factor is a secreted angiogenic mitogen”.
Park et al., 1994,J. Biol. Chem.,269:25646-25654 “Placenta Growth Factor: Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo and high affinity binding to Flt-1 but not to Flk-1/KDR”.
Quinn et al., 1993,Proc. Natl. Acad. Sci. USA,90:7533-7537 “Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium”.
Shibuya et al., 1990,Oncogene,5:519-524 “Nucleotides Sequence and Expression of a Novel Human Receptor-Type/tyrosine Kinase Gene (flt) Closely Related to the fms Family”.
Terman et al.,Oncogene,6:1677-1683 “Identification of a new endothelial cell growth factor receptor tyrosine kinase”.
Weidner et al., 1991,New Engl. J. Med.,324:1-8 “Tumor angiogenesis and metatasis-correlation in invasive breast carcinoma”.
Wiesmann et al., 1997,Cell,91:695-701 “Crystal Structure at 1.7 A Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor”.
Aiello et al., “Suppression of Retinal Neovascularization in vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,”Proc. Natl. Acad. Sci. USA,92(23):10457-10461 (1995).
Borg, et al., “Biochemical characterization of Two Isoforms of FLT4, a VEGF Recetpor-Related Tyrosine Kinase,” Oncogene, 10(5):973-984. (1995).
Chamow, S.M., et al. “Immunoadhesins: principles and applications”,TIBTECH,vol. 14, pp. 52-60 (1996).
Cheon et al., “High-Affinity Binding Sites for Related Fibroblast Growth Factor Ligands Reside within Different Receptor Immunoglobulin-like Domains,”Proc. Natl. Acad. Sci. USA,91:989-993 (1994).
Creighton,Proteins,WH Freeman and Company: New York, NY, pp. 223-227 (1984).
Cunningham, S.A., “Identification of the Extracellular Domains of Flt-1 That Mediate Ligand Interactions”,Biochemical and Biophysical Research Communications,231: pp. 596-599 (1997).
Davis-Smyth, T., et al. “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade”,The EMBO Journal,vol. 15, No. 18, pp. 4919-4917 (1996).
Ferrara et al., “The Vascular Endothelial Growth Factor Family of Polypeptides,”Journal of Cellular Biochemistry,47:211-218 (1991).
Heidaran et al., “PDGFR-IgG Chimera Demonstrates that Human PDGFR Ig-like Domains 1 to 3 are Sufficient for High Affinity PDGF BB Binding,”FASEB J.,9:140-145 (1995).
Kendall and Thomas, “Inhibition of Vascular Endothelial Cell Growth Factor Activity by an Endogenously Encoded Soluble Receptor,”Proc. Natl. Acad. Sci. USA,90:10705-10709 (1993).
Klein,Immunology: The Science of Self-Nonself Discrimination,Wiley-Interscience: New York, NY, pp. 160-161 and 190-191 (1982).
Park et al., “Placenta Growth Factor: Potentiation of Vascular Endothelial Growth Factor Bioactivity, in vitro and in vivo, and High Affinity Binding to Flt-2 But Not to Flk-1/KDR,”J. Biol. Chem.,269(41):25646-25654 (1994).
Plowman et al., “Receptor Tyrosine Kinases as Targets for Drug Intervention,”DN&P,7(6):334-339 (1994).
Rockwell et al., “In vitro Neutralization of Vascular Endothelial Growth Factor Activation of Flk-1 by a Monoclonal Antibody,”Molecular and Cellular Differentiation,3(1):91-109 (1995).
Schulz et al.,Principles of Protein Structure,Springer-Verlag: New York, NY, pp. 14-16 (1979).
Shibuya, et al., “Nucleotides Sequence and Expression of a Novel Human Receptor-Type /tyrosine Kinase Gene (flt) Closly Related to the fms Family,” Oncogene, 5(4):519-524.
Tischer et al., “The Human Gene for Vascular Endothelial Growth Factor,”The Journal of Biological Chemistry,266(18):11947-11954 (1991).
Tischer et al., “Vascular Endothelial Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family,”Biochemical and Biophysical Research Communications,165(3):1198-1206 (1989).
Chen Helen Hsifei
Davis-Smyth Terri Lynn
Ferrara Napoleone
Presta Leonard
Andres Janet
Genentech Inc.
Merchant & Gould P,C,
LandOfFree
Inhibitors of vascular endothelial growth factor activity,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of vascular endothelial growth factor activity,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of vascular endothelial growth factor activity,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3449578